Enjaymo Market Report 2026

Enjaymo Market Overview

• The Enjaymo market growth in the historic period has been driven by limited treatment options for cad, rising diagnosis of rare autoimmune disorders • Market expansion is supported by expansion of complement inhibitor pipelines, increasing awareness of rare hemolytic diseases • Growth Driver: Rising Prevalence Of Autoimmune Disorders Driving Enjaymo Market Growth • Market Trend: Regulatory Approvals Drive Innovation And Accessibility In The Enjaymo Market • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Enjaymo Market?

Enjaymo (sutimlimab) is a complement inhibitor approved for treating cold agglutinin disease (CAD) in adults, a rare autoimmune hemolytic anemia where the immune system destroys red blood cells in cold temperatures. It works by blocking the C1s protein in the classical complement pathway, preventing red blood cell destruction and reducing the need for blood transfusions. The main types of clinical indications in enjaymo are cold agglutinin disease (CAD), Autoimmune Hemolytic Anemia (AIHA), Complement-Mediated Hemolytic Disorders, and Off-Label Uses (Emerging Indications). Cold agglutinin disease is a rare type of autoimmune hemolytic anemia in which the body's immune system produces cold-reactive autoantibodies called cold agglutinins. It is divided by various drug classes, including monoclonal antibodies, corticosteroids, immunosuppressants, and other biological therapies, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Enjaymo Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of complement inhibitor pipelines, increasing awareness of rare hemolytic diseases, improved diagnostic capabilities, supportive orphan drug incentives, growth in specialty biologic adoption. Major trends in the forecast period include complement pathway targeted therapies, growth in rare autoimmune disease treatments, shift toward precision immunology, reduction in transfusion dependent therapies, expansion of orphan drug development.

What Are The Drivers Of The Enjaymo Market?

The increasing prevalence of autoimmune disorders is expected to propel the growth of the enjaymo market going forward. Autoimmune disorders refer to a group of diseases where the immune system, which normally defends the body against harmful invaders such as bacteria and viruses, mistakenly attacks the body's own healthy tissues and organs. The rising prevalence of autoimmune disorders is attributed to improved diagnostics, environmental changes, dietary shifts, sedentary lifestyles, and factors like chronic stress and the hygiene hypothesis affecting immune system regulation. Enjaymo, a monoclonal antibody therapy, helps patients with autoimmune disorders by targeting and inhibiting the complement system, specifically C1s, thereby preventing the activation of the immune response that contributes to the destruction of red blood cells, offering significant relief from hemolytic anemia associated with conditions like cold agglutinin disease and other autoimmune hemolytic disorders. For instance, in February 2024, according to Clinical Trials Arena, a UK-based clinical trials and pharmaceutical developments platform, Projected trends indicate that rheumatoid arthritis (RA) cases worldwide are expected to rise sharply, with prevalence anticipated to grow by 80.2% and affect nearly 1% of the global population by 2050. Therefore, increasing prevalence of autoimmune disorders is driving the growth of the enjaymo industry. An increasing number of clinical trial approvals are expected to propel the growth of the enjaymo market going forward. Clinical trial approvals refer to the process in which regulatory agencies review and grant permission for a clinical trial to begin. The increase in clinical trial approvals is driven by advancements in biotechnology, the rise of biologics, more participation from smaller companies, and streamlined regulatory processes aimed at treating rare diseases and unmet medical needs. Clinical trial approvals for treatments such as enjaymo involve clinical trials, regulatory review for safety and efficacy, and expedited pathways for rare diseases, followed by post-market monitoring. For instance, in July 2024, according to the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, in the second quarter of 2024, 76 gene therapy trials were initiated, marking a 25% increase compared to the previous quarter. Therefore, an increasing number of clinical trial approvals are expected to propel the growth of the enjaymo industry.

Key Players In The Global Enjaymo Market

Major companies operating in the enjaymo market are Recordati Industria Chimica e Farmaceutica S.p.A.

Global Enjaymo Market Trends and Insights

Key trend in the enjaymo market include obtaining regulatory approvals for drugs to enhance treatment accessibility and ensure compliance with global healthcare standards. Regulatory approvals refer to the official authorization granted by governmental or regulatory bodies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), allowing a drug to be marketed and sold. For instance, in January 2023, Sanofi S.A., a France-based pharmaceutical industry company, received FDA approval for Enjaymo (sutimlimab-jome), allowing its use in adults with cold agglutinin disease (CAD) regardless of transfusion history. Enjaymo works by targeting the classical complement pathway, preventing the immune system from attacking red blood cells. The updated formulation also offers a more convenient administration method, reducing infusion time to one hour biweekly. This approval represents a significant advancement in treatment options for CAD patients, enhancing their quality of life.

What Defines the Enjaymo Market?

The enjaymo market consists of sales of products including injection, and drug. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Enjaymo Market Report 2026?

The enjaymo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the enjaymo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.